Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Novavax (NVAX)

NVAX RSS Feed
Add NVAX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BigBake1, LongRun8, TRUTH
Search This Board:
Last Post: 10/17/2014 9:28:55 AM - Followers: 121 - Board type: Free - Posts Today: 0

ABOUT NOVAVAX:

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The company is developing a portfolio of vaccine candidates targeting seasonal and pandemic influenza (H5N1), a vaccine designed to protect children and the elderly against respiratory syncytial virus (RSV), rabies and other candidates. In addition, the company is developing its vaccine candidates for worldwide commercialization including:

Our world-class scientific team is using VLP technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccine candidates that are in various phases of clinical testing designed to protect against various circulating strains of pandemic influenza including H1N1 and H5N1, as well as seasonal influenza. Our recombinant nanoparticle protein micelle technology targeted at RSV has been tested in various preclinical studies and has now advanced into clinical testing.

Our vision is to control the spread of infectious diseases by using a unique single-use manufacturing system that allows for the rapid mass production of recombinant protein nanoparticle vaccines. Our goal is to be able to rapidly deliver a customized vaccine in the midst of a declared pandemic.
 


MANAGEMENT TEAM:

President and Chief Executive Officer
Stanley C. Erck

Senior Vice President, Research and Development
Gregory M. Glenn, M.D.

Senior Vice President, Manufacturing and Process Development
Timothy J. Hahn, Ph.D.

Senior Vice President, Chief Financial Officer and Treasurer
Barclay A. "Buck" Phillips

Senior Vice President, Business Development
Russell P. "Rip" Wilson

Vice President, Regulatory Affairs
Amy B. Fix

Vice President, Chief Medical Officer
Louis F. Fries III, M.D.

Vice President, Manufacturing
Mervyn L. Hamer

Vice President, General Counsel and Corporate Secretary
John A. Herrmann III, J.D.

Vice President, Process Development
Erica Shane, Ph.D.

Vice President, Vaccine Development
Gale Smith, Ph.D.

Vice President, Clinical Operations
D. Nigel Thomas, Ph.D.



CLINICAL-STAGE PIPELINE:

Novavax’s clinical program includes vaccine candidates designed to address infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Our clinical pipeline is shown below.



ADJUVANT PIPELINE:





CHARTS:



 


LINKS:

http://www.novavax.com/
http://finance.yahoo.com/q/h?s=NVAX
http://www.novavax.com/download/File/Interphex.pdf
http://www.sec.gov/cgi-bin/browse-edgar?company=Novavax&CIK=&filenum=&State=&SIC=&owner=include&action=getcompany
http://www.wipo.int/pctdb/en/wo.jsp?WO=2008061243


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVAX
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for NVAX
NVAX News: Statement of Changes in Beneficial Ownership (4) 10/06/2014 10:16:37 AM
NVAX News: Statement of Changes in Beneficial Ownership (4) 10/03/2014 04:28:34 PM
NVAX News: Statement of Changes in Beneficial Ownership (4) 09/26/2014 05:03:14 PM
NVAX News: Statement of Changes in Beneficial Ownership (4) 09/26/2014 04:56:39 PM
NVAX News: Current Report Filing (8-k) 09/24/2014 04:16:47 PM
PostSubject
#1988   A think a combination of things has pushed BigBake1 10/17/14 09:28:55 AM
#1987   Nice! I thought I was an idiot for underdog150 10/16/14 07:04:56 PM
#1986   Hellloooo $5.20's again.... missed them... Still an hour BigBake1 10/16/14 02:46:30 PM
#1985   As the market is in correction it is BigBake1 10/16/14 10:14:14 AM
#1984   Short Interest in Novavax Rises By 5.9% (NVAX) TRUTH 10/11/14 04:00:25 PM
#1983   This thing is thin, quick pop to $4.56 BigBake1 10/07/14 10:57:47 AM
#1982   Novavax’ H7N9 Avian Influenza VLP Vaccine Candidate with TRUTH 10/07/14 10:17:08 AM
#1981   Novavax (NVAX) PT Boosted at Piper Jaffray; 145% TRUTH 10/07/14 10:05:30 AM
#1980   Broke above the 20ma could start to see BigBake1 10/07/14 10:04:50 AM
#1979   Novavax Coverage Initiated by Analysts at JPMorgan Chase TRUTH 10/07/14 09:58:41 AM
#1978   JP Morgan Initiates Novavax At Overweight TRUTH 10/07/14 09:52:21 AM
#1977   Market is down and yet this is going BigBake1 10/07/14 09:43:25 AM
#1976   At 14% of the Float it is a BigBake1 10/06/14 04:28:09 PM
#1975   I bet the 32 million shares short have underdog150 10/06/14 11:57:01 AM
#1974   It quite the paradox here, never have I BigBake1 10/06/14 10:29:21 AM
#1973   massive volume that spiked from 4.11 to 4.25 rand0m 10/06/14 10:25:12 AM
#1972   Jees! Great to hear...hope they make it before ebola...?? MRatt 10/05/14 10:14:12 AM
#1971   Novavax working on Ebola underdog150 10/05/14 08:01:25 AM
#1970   There is just no headway, a complete sideways BigBake1 10/01/14 04:26:51 PM
#1969   so oversold down here! will fly tomorrow, I rand0m 10/01/14 03:10:58 PM
#1968   This is the news that is needed, I BigBake1 09/23/14 10:06:37 AM
#1967   Novavax Announces BARDA Exercise of Contract Option LongRun8 09/23/14 09:09:42 AM
#1966   Novavax' H7N9 Avian Influenza VLP Vaccine Candidate With LongRun8 09/23/14 09:08:44 AM
#1965   Short volume high Tate 09/22/14 11:43:50 AM
#1964   Keep in mind the BARDA extension for an BigBake1 09/06/14 07:41:30 PM
#1963   Why Merck should acquire Novavax underdog150 09/06/14 06:57:15 PM
#1962   You are right! nomorebanksters 08/19/14 07:50:42 AM
#1961   agreed. just as before: buy the Dips and goforthebet 08/07/14 11:43:38 AM
#1960   I had a feeling the price was being BigBake1 08/07/14 11:31:37 AM
#1959   this guy better would have waited until today goforthebet 08/07/14 11:09:36 AM
#1958   Yeah so that is the question, what are BigBake1 08/05/14 10:49:38 AM
#1957   Even better! That's good news. The LongRun8 08/05/14 10:47:48 AM
#1956   Well checking back these are already registered so BigBake1 08/05/14 10:23:33 AM
#1955   Ah, forgot about that. How long are LongRun8 08/05/14 09:44:59 AM
#1954   Well the shares they purchased yesterday are restricted BigBake1 08/05/14 09:35:52 AM
#1953   Exactly. And they did the same thing LongRun8 08/05/14 09:32:25 AM
#1952   Well we know they had a stack of BigBake1 08/05/14 09:30:43 AM
#1951   curious what they have to tell us :) goforthebet 08/05/14 09:27:59 AM
#1950   It is a good thing, they are exercising BigBake1 08/05/14 09:26:32 AM
#1949   Insider buying - not a bad thing :) goforthebet 08/05/14 09:11:57 AM
#1948   Hopefully next weeks Q2 report is on target BigBake1 07/30/14 06:17:26 PM
#1947   Meant to post this a couple of days LongRun8 07/30/14 12:35:22 PM
#1946   Antiviral-drug maker fights pediatricians' new advice LongRun8 07/30/14 12:32:58 PM
#1945   -Barrons analytics target is 9-14 STONG BUY sedrik 07/24/14 04:06:48 AM
#1944   NVAX = strong strong buying opportunity! Spread the word! BCLBCL 07/23/14 08:40:36 AM
#1943   Haha that's how much the report costs lol StickyStock 07/23/14 08:39:13 AM
#1942   http://www.reuters.com/finance/stocks/analystResearch?symbol=NVAX.O analytics t sedrik 07/23/14 06:31:46 AM
#1941   Analyst REPORT NVAX 22 JUl 2014 target $25.00 sedrik 07/23/14 06:29:30 AM
#1940   Novavax, Inc. [$NVAX] due diligence stocktrademan 07/07/14 11:08:23 AM
#1939   $5 test coming again...watch for breakout. http://stockcharts.com/h-sc/ui?s=NVAX&p=D&b=5&amp fais007 06/25/14 06:50:12 PM
PostSubject